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Background: We explore the clinical and prognostic significance of expression of vascular endothelial growth
factor receptor (VEGFR)-2, platelet-derived growth factor receptor (PDGFR)-β, and c-Met in patients with
hepatocellular carcinoma (HCC).
Methods: The expression of VEGFR-2, PDGFR-β, and c-Met were determined by immunohistochemical examination
of the tissues of 93 HCC patients. The relationships of these markers with clinicopathological factors and prognosis
were then analyzed.
Results: High expression of VEGFR-2, PDGFR-β, and c-Met was found in 86%, 19.4%, and 80.6% of patients,
respectively. Expression of VEGFR-2 correlated with gender (P = 0.044), hepatitis B surface antigen positivity
(P = 0.024), degree of tumor differentiation (P = 0.023), and hepatic cirrhosis (P = 0.026). Expression of PDGFR-β
correlated with alpha-fetoprotein level (P = 0.029), tumor size (P = 0.033), and hepatic cirrhosis (P = 0.023). No
significant correlations were identified between expression of c-Met and clinicopathological factors. Expression of
PDGFR-β correlated with overall survival (P = 0.046) and expression of c-Met correlated with progression-free
survival (P = 0.01).
Conclusions: We found that in patients with HCC, high expression of VEGFR-2 correlates with chronic hepatitis B
virus infection and hepatic cirrhosis. High expression of PDGFR-β is a predictor of poor prognosis. High expression
of C-Met may predict therapeutic effectiveness of sorafenib in HCC patients.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignant tumor worldwide, with over 600,000
new cases diagnosed each year, and is the third most
common tumor-related cause of death [1]. Hepatitis B
virus (HBV) infection, hepatitis C virus infection, and
aflatoxin-induced oncogene activation and tumor sup-
pressor gene inactivation are the main causes of HCC* Correspondence: a.paradiso@oncologico.bari.it; jmxu2003@yahoo.com
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reproduction in any medium, provided the or[2]. Surgical resection and liver transplantation may cure
HCC, but about 85% of patients have locally advanced
tumor or distant metastasis at the time of diagnosis, and
are not suitable candidates for surgery [3]. Conventional
chemotherapy for HCC has limited effectiveness, but
recent breakthroughs in treatment with molecular-
targeted drugs have been reported.
Abnormalities of intracellular signaling pathways which
result in abnormal cell proliferation and apoptosis are one
of the main mechanisms of HCC development. Many
complex cellular signaling pathways are involved in tumor
development and growth. These pathways include pro-
teins such as vascular endothelial growth factor (VEGF),
VEGF receptor (VEGFR), platelet-derived growth factor
(PDGF), PDGF receptor (PDGFR), hepatocyte growth. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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High expression of VEGFR-2, PDGFR-β, and c-Met can
be detected in many tumors, including HCC, but informa-
tion regarding the relationships between expression of
VEGFR-2, PDGFR-β, and c-Met and the clinicopathologi-
cal factors and prognosis of HCC is very limited [4-7].
This study explored the relationships between expression
of VEGFR-2, PDGFR-β, and c-Met and the clinicopatho-
logical factors and prognosis of HCC patients, aiming to
provide reference information to assist with the diagnosis,
evaluation of prognosis, and targeted therapy of HCC.
Methods
Specimens were collected from 93 HCC patients treated at
the Department of Digestive Oncology, Chinese People's
Liberation Army 307 Hospital from January 2007 to Octo-
ber 2011. The specimens were collected from patients by
biopsy and it was excluded if the biopsy specimen was too
less. Sixty-five of these patients were taking sorafenib. All
patients met the following inclusion criteria: (1) advanced
stage HCC which was not suitable for surgery or local treat-
ment, or had recurred after surgery or local treatment, (2)
Child-Pugh class A or B, (3) Eastern Cooperative Oncology
Group (ECOG) score 0 or 1, (4) at least one target lesion
that had not been previously treated, (5) no local treatment
for at least 4 weeks before baseline imaging, (6) availability
of complete clinical and pathological data, including follow-
up data. All specimens were fixed in 10% formaldehyde,
embedded in paraffin, and cut into 4-μm thick slices before
staining. Clinical and pathological data of all patients, and
progression-free survival (PFS) and overall survival (OS)
data of the 65 patients who took sorafenib, were obtained
from medical records and telephone follow-ups, with a
follow-up deadline of November 11, 2011. The clinical
and pathological data collected included gender, age,
hepatitis B surface antigen (HBsAg) status, serum alpha-
fetoprotein (AFP) level, tumor number, tumor size, degree
of tumor differentiation, Child-Pugh class, Barcelona
Clinic Liver Cancer (BCLC) stage, presence of cirrhosis,
ascites, tumor thrombus, and extrahepatic metastasis. The
PFS and OS were defined as the time from initiation of
sorafenib therapy to the time of disease progression
detected by computed tomography or magnetic resonance
imaging, or death, respectively.
Immunohistochemical staining
Expression of VEGFR-2, PDGFR-β, and c-Met were deter-
mined by two-step PV-6000 immunohistochemistry stain-
ing. Specimen slices were dewaxed, rinsed in phosphate-
buffered saline (PBS). Antigen retrieval was performed by
placing the slides in a high pressure cooker in 0.01 mmol/
L citrate buffer, pH 6.0, for 3 minutes at 100°C, followed
by cooling for 20 min at room temperature, rinsing in
PBS, treating with 3% hydrogen peroxide in deionizedwater for 10 min to block endogenous peroxidase, and
rinsing again in PBS. Specimens were then incubated at
37°C for 1 hour with primary antibody against VEGFR-2
(dilution ratio 1:50; Santa Cruz Biotechnology Inc., Santa
Cruz, CA), PDGFR-β (dilution ratio 1:40; Santa Cruz
Biotechnology Inc., CA), and c-Met (rabbit anti-human c-
Met monoclonal antibody working solution; Epitomics,
California, US), followed by rinsing three times in PBS
for 2 min each time. Specimens were incubated at 37°C
for 20 min with universal IgG antibody-HRP polymer
(Zhongshan Jinqiao Co., Beijing, China), and rinsed three
times in PBS for 2 min each time. Specimens were placed
in DAB solution for color development, rinsed with dis-
tilled water, stained again, dehydrated, and sealed with
transparent strips. Primary antibodies were replaced with
PBS to produce a negative control, and a known positive
tissue slice was used as a positive control.
Analysis of immunohistochemistry results
Two pathologists who were blind to diagnosis independ-
ently inspected the slices. The rate of agreement between
the two pathologists was 95%. The scores from both pa-
thologists were averaged to provide the final score for each
case. A combination of positive cell count and staining in-
tensity was used for scoring. Positive cell count was scored
based on the average percentage of positive cells per 100
cells in 10 high-power fields, as follows: 0–10%, score 0;
11–25%, score 1; 26–50%, score 2; 51–75%, score 3; and
>75%, score 4. Staining intensity was scored as follows:
negative, score 0; faint yellow, score 1; yellow or deep yel-
low, score 2; brown or dark brown, score 3. The final score
was obtained by multiplying the cell count and staining in-
tensity scores. For VEGFR-2 and c-Met, a score of ≥ 5 was
defined as high expression and a score of < 5 was defined
low expression. For PDGFR-β, a score of ≥ 3 was defined as
high expression group and a score of < 3 was defined as
low expression.
Statistical analysis
Statistical analyses were performed using SPSS software
version 18.0. Categorical variables were compared using
the χ2 test or Fisher's exact test. Survival rates were calcu-
lated using the Kaplan-Meier method. Univariate survival
analyses were performed using the log-rank test, and
multivariate survival analyses were performed using Cox’s




Expression of VEGFR-2, PDGFR-β, and c-MET in the tissues
of HCC patients
Expression of VEGFR-2, PDGFR- β, and c-MET was
identified by immunohistochemical cytoplasmic staining
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brown, with a granular or clustered distribution (Figure 1).
High expression of VEGFR-2 was observed in 80 of 93
cases (86%), high expression of PDGFR- β was observed
in 18 cases (19.4%), and high expression of c-Met was ob-
served in 75 cases (80.6%).
VEGFR-2, PDGFR-β, c-MET
Relationships between expression of VEGFR-2, PDGFR-β,
and c-Met and clinicopathological factors
Expression of VEGFR-2 correlated with gender, HBsAg
status, degree of tumor differentiation, and hepatic cir-
rhosis, but did not correlate with age, AFP level, tumor
number, tumor size, Child-Pugh class, BCLC stage, asci-
tes, tumor thrombus, or extrahepatic metastasis. High
expression was more frequent in males than females
(89.6% vs, 68.8%, P = 0.044), in HBsAg-positive patients
than HBsAg-negative patients (89.9% vs. 64.3%, P = 0.024),
in well-differentiated tumors than poorly-differentiated tu-
mors (100% vs. 72.7%, P = 0.023), and in patients with cir-
rhosis than without cirrhosis (93.8% vs, 77.8%, P = 0.026).Figure 1 Expression of VEGFR-2, PDGFR-β, and c-MET in hepatocellula
carcinoma (PV-6000 staining, ×100). B Expression of VEGFR-2 (PV-6000 stain
carcinoma (PV-6000 staining, ×100). D Expression of PDGFR-β (PV-6000 stai
carcinoma (PV-6000 staining, ×100). F Expression of c-MET (PV-6000 staininExpression of PDGFR-β correlated with AFP level, tumor
number, and cirrhosis, but did not correlate with gender,
age, HBsAg status, tumor size, degree of tumor differenti-
ation, Child-Pugh class, BCLC stage, ascites, tumor
thrombus, or extrahepatic metastasis. High expression of
PDGFR-β was more frequent in patients with AFP > 400
IU/mL than with AFP ≤ 400 IU/mL (28.3% vs. 10.6%, P =
0.029), in patients with multiple tumors than with single
tumors (25.0% vs. 6.9%, P = 0.033), and in patients without
cirrhosis than with cirrhosis (28.9% vs. 10.4%, P = 0.023).
There were no significant correlations between expression
of c-MET and clinical or pathological factors, but high ex-
pression of c-Met tended to be more frequent in patients
with BCLC stage C than stage B (84.9% vs 65%, P = 0.051)
(Table 1).
HCC
Relationships between clinicopathological factors and
prognosis
Univariate analyses showed that in the 65 patients who
took sorafenib, PFS time correlated with age and OSr carcinoma. A Expression of cytoplasmic VEGFR-2 in hepatocellular
ing, ×400). C Expression of cytoplasmic PDGFR-β in hepatocellular
ning, ×400). E Expression of cytoplasmic c-MET in hepatocellular
g, × 400).
Table 1 Relationships between expression of VEGFR-2, PDGFR-β, and C-met and clinicopathological factors
Parameters N VEGFR-2 P PDGFR-β P C-MET P
High Low High Low High Low
N(%) 93 80(86.0) 13 18(19.4) 75 75(80.6) 18
Gender
Male 77 69(89.6) 8 15(19.5) 62 61(79.2) 16
Female 16 11(68.8) 5 0.044 3(18.8) 13 0.627 14(87.5) 2 0.355
Age
≤50 31 26(83.9) 5 6(19.4) 25 25(80.6) 6
>50 62 54(87.1) 8 0.448 12(19.4) 50 0.602 50(80.6) 12 0.616
HBsAg
Positive 79 71(89.9) 8 16(20.3) 63 63(79.7) 16
Negative 14 9(64.3) 5 0.024 2(14.3) 12 0.461 12(85.7) 2 0.461
AFP(IU/ML)
≤400 47 39(83.0) 8 5(10.6) 42 39(83.0) 8
>400 46 41(89.1) 5 0.290 13(28.3) 33 0.029 36(78.3) 10 0.377
Tumor number
Single 29 26(89.7) 3 2(6.9) 27 23(79.3) 6
>1 64 54(84.4) 10 0.371 16(25.0) 48 0.033 52(81.3) 12 0.516
Tumor size(cm)
≤5 16 13(81.3) 3 4(25.0) 12 13(81.3) 3
>5 77 67(87.0) 10 0.394 14(18.2) 63 0.373 62(80.5) 15 0.627
Differentiation
High 26 26(100) 0 7(26.9) 19 21(80.8) 5
Middle 45 38(84.4) 7 6(13.3) 39 35(77.8) 10
Low 22 16(72.7) 6 0.023 5(22.7) 17 0.340 19(86.4) 3 0.705
Child-Pugh
A 82 70(85.4) 12 14(17.1) 68 64(78.0) 18
B 11 10(90.9) 1 0.523 4(36.4) 7 0.134 11(100) 0 0.080
BCLC
B 20 15(75.0) 5 2(10.0) 18 13(65.0) 7
C 73 65(89.0) 8 0.111 16(21.9) 57 0.194 62(84.9) 11 0.051
Hepatic cirrhosis
Yes 48 45(93.8) 3 5(10.4) 43 37(77.1) 11
No 45 35(77.8) 10 0.026 13(28.9) 32 0.023 38(84.4) 7 0.263
Ascites
Yes 19 17(89.5) 2 3(15.8) 16 17(89.5) 2
No 74 63(85.1) 11 0.476 15(20.3) 59 0.470 58(78.4) 16 0.228
Tumor thrombus
Yes 38 33(86.8) 5 10(26.3) 28 34(89.5) 4
No 55 47(85.5) 8 0.551 8(14.5) 47( 0.126 41(74.5) 14 0.061
Extrahepatic metastasis
Yes 48 43(89.6) 5 8(16.7) 40 40(83.3) 8
No 45 37(82.2) 8 0.235 10(22.2) 35 0.339 35(77.8) 10 0.339
VEGFR-2, vascular endothelial growth factor receptor-2; PDGFR-β, platelet-derived growth factor receptor-β; C-MET, hepatocyte growth factor receptor; HbsAg,
hepatitis B surface antigen; AFP, serum alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer stage.
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tumor thrombus (Table 2). PFS time was longer in pa-
tients aged > 50 years than those aged ≤ 50 years (5.83
months vs. 4.00 months, P = 0.047). OS time was longer
in patients with an AFP level ≤ 400 IU/mL than an AFP
level > 400 IU/mL (11.13 months vs. 5.20 months, P =
0.022), in patients with a tumor size ≤ 5 cm than a
tumor size > 5 cm (29.27 months vs. 5.87 months, P =
0.002), in patients without ascites than with ascites (8.97
months vs. 5.00 months, P = 0.049), and in patients
without tumor thrombus than with tumor thrombus
(11.37 months vs. 5.00 months, P = 0.005). Multivariate
analyses showed that PFS time was independently corre-
lated with age (P = 0.047) and OS time was independ-
ently correlated with HBsAg positivity (P = 0.037), AFP
level (P = 0.015), and tumor size (P = 0.003).Table 2 Univariate analyses of the relationships between clin
Parameters N
Months
Gender Male 55 4.433
Female 10 6.200
Age ≤50 22 4.000
>50 43 5.833
HBsAg Positive 55 4.433
Negative 10 5.833
AFP(IU/ml) ≤400 31 7.000
>400 34 4.233
Tumor number Single 18 5.600
>1 47 4.967
Tumor size(cm) ≤5 12 7.300
>5 53 4.367
Differentiation High 17 6.200
Middle 33 4.367
Low 15 4.000
Child-Pugh A 59 5.600
B 6 4.967
BCLC B 7 5.633
C 58 4.433
Hepatic cirrhosis Yes 34 4.967
No 31 4.433
Ascites Yes 14 4.367
No 51 5.600
Tumor thrombus Yes 28 3.000
No 37 5.833
Extrahepatic metastasis Yes 41 4.367
No 24 5.600
PFS, progression-free survival; OS, overall survival; HbsAg, hepatitis B surface antigeVEGFR-2, PDGFR-β, c-MET
Relationships between expression of VEGFR-2, PDGFR-β,
and c-MET and prognosis in patients who took sorafenib
We used the Kaplan-Meier method and log-rank test to
analyze the association between the expression of
VEGFR-2, PDGFR-β, c-Met and prognosis. Among the
65 patients who took sorafenib, there was no significant
difference between patients with high and low expres-
sion of VEGFR-2 in PFS time (P = 0.532) or OS time (P
= 0.473). There was no significant difference between
patients with high and low expression of PDGFR-β in
PFS time (P = 0.246), but the median OS time was
shorter in patients with high expression of PDGFR-β
than low expression of PDGFR-β (5.87 months vs. 8.97
months, P = 0.046). The median PFS time was longer in
patients with high expression of c-MET than lowicopathologic factors and survival
PFS OS
χ2 P Months χ2 P
7.400
0.609 0.435 10.200 0.340 0.560
5.867
3.934 0.047 8.067 0.113 0.736
6.467
0.516 0.472 8.800 3.608 0.057
11.133
3.016 0.082 5.200 5.236 0.022
8.967
0.168 0.682 5.867 0.981 0.322
29.267
3.792 0.051 5.867 9.834 0.002
5.233
8.967
3.630 0.163 5.667 3.097 0.213
8.067
0.599 0.439 3.600 1.980 0.159
10.500
3.527 0.060 7.400 0.274 0.600
6.533
0.002 0.965 8.967 0.194 0.659
5.000
2.706 0.100 8.967 3.887 0.049
5.000
2.800 0.094 11.367 8.067 0.005
6.467
0.878 0.349 8.967 0.017 0.897
n; AFP, serum alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer stage.
Table 3 Relationships between expression of VEGFR-2,
DGFR-β, and c-MET and prognosis in HCC patients who
took sorafenib
N PFS OS
Months χ2 P months χ2 P
PDGFR-β 65
High 13 4.23 5.87
Low 52 5.60 1.345 0.246 8.97 3.996 0.046
VEGFR-2 65
High 58 4.97 7.40
Low 7 7.93 0.391 0.532 11.37 0.514 0.473
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0.010), but there was no significant difference in OS
time between patients with high and low expression of
c-Met (Figure 2, Table 3).
Discussion
The pathogenesis of HCC is believed to multifactorial.
HBV infection and hepatic cirrhosis are known risk fac-
tors. In China, most patients with HCC have both HBV
infection and cirrhosis. The specific signaling pathways
and key proteins involved in the development of HCC


































Figure 2 Kaplan-Meier curves were plotted for PFS and OS.
Patients were divided into high-expression group and low-
expression group by PDGFR-β expression or c-MET expression.
A: Overall survival curves stratified by PDGFR-β expression (p=0.046).
B: Progression-free survival curves stratified by c-MET expression
(p=0.010). PFS, progression-free survival; OS, overall survival.
c-MET 65
High 55 5.60 8.97
Low 10 1.43 6.558 0.010 6.47 0.930 0.335
VEGFR-2, vascular endothelial growth factor receptor-2; PDGFR-β, platelet-
derived growth factor receptor-β; C-MET, hepatocyte growth factor receptor;
PFS, progression-free survival; OS, overall survival.proteins were confirmed to play an important role in the
process, including VEGFR. Lian et al. [8] reported that
hepatitis B x antigen was involved in the upregulation of
VEGFR-3, which may be associated with the develop-
ment of HCC. Corpechot et al. [9] reported that hepato-
cellular hypoxia led to angiogenesis and hepatic fibrosis
in an animal model of cirrhosis, and that upregulation of
the expression of VEGF and VEGFR-2 correlated with
increased density of microvessels. Kornek et al. [10]
reported that hepatic fibrosis may promote the develop-
ment of HCC, and that VEGF-A and VEGFR-A may
contribute to accelerated development of HCC. DeLeve
et al. [11] reported that liver sinusoidal endothelial cells
may secrete matrix metalloproteinase MMP2 and
MMP9, and that MMP9 may cause the degradation of
endothelial cells and thrombosis, resulting in sinusoidal
obstruction syndrome. VEGF may promote MMP activ-
ity, thereby exacerbating the liver injury. Serum VEGF
level is therefore related to the degree of liver injury.
Ribero et al. [12] reported that patients with liver metas-
tasis from colorectal cancer often had liver damage after
taking oxaliplatin- or irinotecan-based chemotherapy,
but the incidence and severity of this liver injury were
significantly reduced when bevacizumab (VEGF McAb)
was added. This indicates that high expression of VEGF
in cirrhotic liver tissue is associated with the develop-
ment and severity of cirrhosis. Inhibition of VEGF ex-
pression can reduce the incidence and severity of
hepatic cirrhosis. This study also found high expression
of VEGFR-2 in HCC patients with HBsAg positivity and
hepatic cirrhosis. We speculate that expression of VEGF
and VEGFR is upregulated in response to liver cell hyp-
oxia resulting from HBV infection and cirrhosis, leading
to angiogenesis. The resulting new blood vessels may
provide the foundation for the development of tumor
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of VEGF expression in patients with hepatic cirrhosis
may prevent the development of cancer. This possibility
requires further investigation.
HCC has a relatively poor prognosis, with a median
survival time of only 6–9 months [1,13]. Although the
Child-Pugh classification gives a relatively reliable indica-
tion of prognosis, some researchers prefer to use other
indices such as the Cancer of the Liver Italian Program
(CLIP) stage, BCLC stage, or Model for End-stage Liver
Disease (MELD) stage. Although many studies have
reported on the prognostic value of protein markers of liver
cancer, there is no consensus regarding the use of these
markers to predict prognosis. The results of the current
study show that age, AFP level, tumor size, ascites, and
tumor thrombus may correlate with the prognosis of HCC
patients, and should probably be taken into account to-
gether with the Child-Pugh classification when considering
prognosis. Our analyses found that OS time was shorter in
patients with high expression of PDGFR-β than low expres-
sion of PDGFR-β, and that high expression of PDGFR-β
correlated with AFP level > 400 IU/mL and multiple tu-
mors. AFP level > 400 IU/mL and multiple tumors are indi-
cators of poor prognosis in HCC patients, which suggests
that high expression of PDGFR-β is also an indicator of
poor prognosis. This conclusion is consistent with other re-
cent research. Chen et al. [7] reported that simultaneous
high expression of PDGFR-α, PDGFR-β, and VEGF was a
predictor of poor prognosis in patients with HCC.
Patel et al. [14] also reported that high expression of
both PDGFR-α and PDGFR-β was an independent pre-
dictor of shorter OS time. Expression of PDGFR in pa-
tients with HCC may therefore be a useful indicator of
prognosis.
Current comprehensive treatment of HCC includes
molecular-targeted therapy. Sorafenib is currently the
only molecular-targeted drug approved for the treatment
of HCC. Two Phase III clinical trials [15,16] reported
that sorafenib controlled disease in 43% and 35% of
HCC patients, respectively, indicating that the majority
of patients do not benefit from this treatment. As there
are currently no known biological markers which can
predict the efficacy of sorafenib treatment, evaluation of
potential markers is very important. Researchers have
evaluated many potential predictors of the effectiveness
of sorafenib treatment, including clinical staging systems.
Baek et al. [17] reported that the Cancer of the Liver
Italian Program score or Okuda stage, together with per-
formance status, could be used to predict the effectiveness
of sorafenib treatment. Morimoto et al. [18] considered
that the Glasgow Prognostic Score had a significant prog-
nostic value. Song et al. [19] reported that ascites and dis-
tant metastasis predicted poor effectiveness, and that side
effects of sorafenib treatment predicted good effectiveness.Pinter et al. [20] reported that low levels of AFP and ALT,
Child-Pugh class B, and compensated cirrhosis were pre-
dictors of a good response to sorafenib treatment, and that
AST level could be used to predict whether Child-Pugh
class B patients would benefit from sorafenib treatment.
Lee et al. [21] reported that patients with a low FDG up-
take on positron-emission tomography might benefit
from sorafenib treatment. Kondo et al. [22] reported
that high expression of c-MET correlated with portal
vein tumor thrombus, and that postoperative
recurrence-free survival was significantly poorer in pa-
tients with high expression of c-Met than with low ex-
pression of c-Met. Expression of c-MET may be a
predictor of postoperative recurrence in HCC patients.
Our results did not show a significant difference in the
frequency of portal vein tumor thrombus between pa-
tients with high and low expression of c-MET (89.5% vs.
74.5%, P = 0.061), which is probably because our assess-
ment of tumor thrombus was based on imaging results,
whereas Kondo et al. [22] based their assessment on
pathological findings. Albig et al. [23] reported that high
expression of c-Met may enhance the sensitivity of can-
cer tissues to hepatocyte growth factor, thereby increas-
ing the invasiveness of cancer cells and the likelihood of
metastasis. Combination of the results reported by
Kondo et al. [22] and Albig et al. [23] suggests that pa-
tients with high expression of c-Met have a poor prog-
nosis. However, our survival analyses show that in
patients who took sorafenib, PFS time was longer in pa-
tients with high expression of c-Met than low expres-
sion of c-Met (5.60 months vs. 1.43 months, P = 0.010),
suggesting that expression of c-MET may predict the ef-
fectiveness of sorafenib treatment in HCC patients.
These results require further evaluation in studies with
larger sample sizes and more carefully selected patients.
From the statistic results, the median PFS time was lon-
ger in patients with high expression of c-MET than
those in low expression of c-MET (5.60 months vs. 1.43
months, P = 0.010), but there was no significant differ-
ence in OS time between patients with high and low
expression of c-Met, We considered the subsequent
treatments after sorafenib may cause the discrepancy of
longer PFS and no significant OS. In China, Patients
with HCC usually received other treatments after failure
to sorafenib, such as intervention therapy and Chinese
herbal medicine and so on.
Conclusions
In summary, our finding that HCC with hepatic cirrhosis
is associated with high expression of VEGFR-2 provides
new information to help our understanding of the devel-
opment and treatment of hepatic cirrhosis. Age, AFP
level, tumor size, ascites, and tumor thrombus may be
useful prognostic indicators in HCC patients. High
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sis, and high expression of c-MET may predict thera-
peutic effectiveness of sorafenib treatment, allowing
individualized treatment of HCC patients.
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